A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
https://www.facingourrisk.org/research-clinical-trials/study/17/triton3-rucaparib-vs-physician-choice-for-castration-resistant-prostate-cancer
Clinicaltrials.gov identifier:
NCT02975934 (https://clinicaltrials.gov/show/NCT02975934)
Study Contact Information:
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.
About the Study
The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca) compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients.
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
NOTE: This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.